These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 7987990

  • 1. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR.
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [Abstract] [Full Text] [Related]

  • 2. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

  • 3. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR.
    Cancer Res; 1992 Nov 15; 52(22):6188-93. PubMed ID: 1423261
    [Abstract] [Full Text] [Related]

  • 5. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Aug 15; 68(2):240-50. PubMed ID: 8347478
    [Abstract] [Full Text] [Related]

  • 6. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
    Poulain L, Sichel F, Crouet H, Bureau F, Gauduchon P, Gignoux M, Le Talaër JY.
    Cancer Chemother Pharmacol; 1997 Aug 15; 40(5):385-90. PubMed ID: 9272114
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ, Kelland LR.
    Cancer Res; 1994 Dec 01; 54(23):6194-200. PubMed ID: 7954466
    [Abstract] [Full Text] [Related]

  • 8. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 01; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 9. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
    Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR.
    Br J Cancer; 1992 Dec 01; 66(6):1109-15. PubMed ID: 1457352
    [Abstract] [Full Text] [Related]

  • 10. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 01; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ, Abel G, Kelland LR, Harrap KR.
    Br J Cancer; 1994 Jan 01; 69(1):1-7. PubMed ID: 8286188
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
    Ferguson PJ, Currie C, Vincent MD.
    Drug Metab Dispos; 1999 Dec 01; 27(12):1399-405. PubMed ID: 10570020
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
    Sharp SY, Rowlands MG, Jarman M, Kelland LR.
    Br J Cancer; 1994 Sep 01; 70(3):409-14. PubMed ID: 8080723
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR.
    Br J Cancer; 1991 Aug 01; 64(2):215-20. PubMed ID: 1892748
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Kelland LR, Abel G.
    Cancer Chemother Pharmacol; 1992 Aug 01; 30(6):444-50. PubMed ID: 1356649
    [Abstract] [Full Text] [Related]

  • 20. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP, O'Dwyer PJ, Handel LM, Ozols RF, Hamilton TC.
    Int J Cancer; 1991 May 10; 48(2):265-9. PubMed ID: 2019469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.